Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Zack Kubow
executiveThank you, operator, and good afternoon to all of you. We appreciate your joining us for the Corvus Pharmaceuticals conference call covering business updates and financial results for the third quarter of 2026. Here to discuss the results and business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Ben Jones, Senior Vice President of Pharmaceutical Development; and Suresh Mahabhashyam, Vice President of Clinical Development. Our executive team will begin with some prepared remarks, and a question-and-answer period will follow. I want to remind everyone that management's comments today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in the Corvus quarterly report on Form 10-Q for the quarter ended September 30, 2026, and other filings the company makes with the SEC from time to time. Except as required by law, the company undertakes no obligation to publicly update or revise any forward-looking statements. With that, I'd like to turn the call over to Leiv Lea. Leif?
Leiv Lea
executiveThank you, Zack. I'll start with a quick look at the financial results for our third quarter of 2026, and after that I'll hand the call to Richard for a business update. R&D expenses for the third quarter of 2026 came to $17.8 million, versus $8.5 million in the same period of 2025. The rise in R&D spending was driven mainly by greater clinical trial costs tied to developing soquelitinib, along with higher personnel costs. Our net loss in the third quarter of 2026 was $20.3 million, compared with a net loss of $10.2 million in the same period of 2025. Both the third quarter of 2026 and the third quarter of 2025 net losses included non-cash losses of $0.9 million and $0.3 million, respectively, stemming from Corvus's equity method investment in Angel Pharmaceuticals. Stock compensation expense on a total basis for the three months ended September 30th, 2026, was $2.8 million, versus $1.2 million in the same period of 2025. At September 30th, 2026, Corvus held cash, cash equivalents, and marketable securities of $202.9 million in total, compared with $56.8 million at December 31st, 2025. The cash balance at September 30th, 2026, included roughly $189.4 million in net proceeds from a follow-on offering that was completed in Q1. In addition, as we announced on June 9th, 2026, Corvus made a $5 million investment as part of a $13.5 million financing that Angel Pharmaceuticals completed in the second quarter of 2026. Given our cash position at September 30th, 2026, and our current plans, we expect that cash will fund operations into the second quarter of 2028. I'll now turn the call over to Richard, who will walk through our clinical progress and go into more detail on our strategy and plans.
Richard Miller
executiveThanks, Leif, and good afternoon to all of you. I appreciate everyone joining today's update call. Soquelitinib—our first-in-class selective ITK inhibitor—is where our attention is firmly placed, and so is realizing its fullest potential across a wide variety of diseases. At this point, soquelitinib is being studied in multiple clinical trials spanning a range of medical areas. Advancing our two lead opportunities comes first: the registrational Phase 3 study in relapsed/refractory peripheral T-cell lymphoma, along with our Sierra-1 Phase 2 trial in moderate to severe atopic dermatitis. Both of these programs remain on track, and each represents a meaningful chance to deliver much-needed new treatment options to patients. Given soquelitinib's immunologic properties, we are capitalizing on its novel mechanism of action and its broad immunomodulatory profile by deliberately broadening development into additional indications that today's available agents do not serve well; that covers the trial we recently launched in hidradenitis suppurativa, our planned asthma trial spanning T2 and non-T2 patients, and the ALPS trial now under way. Alongside the clinical work being run in China by our partner, Angel Pharmaceuticals, we expect a range of important data readouts and milestones tied to our pipeline during the coming year; with that pipeline, we are well positioned to create substantial value in 2027. I'll begin with a quick update on the Phase 3 study in relapsed/refractory PTCL. Enrollment is proceeding in line with what we expected, and the next milestone is a futility analysis that we anticipate in the first quarter of 2027. As a reminder, an independent data monitoring committee will carry out that futility analysis once a predefined number of progression-free survival, or PFS, events has taken place. It is event-driven rather than time-driven. Looking at the data available at that point, the committee will decide whether the study continues or is stopped for futility, based on the safety and efficacy data on hand. Corvus will not report any safety or efficacy data alongside the interim analysis; what we will disclose is the committee's decision on whether the trial continues or is discontinued. We continue to be enthusiastic about what soquelitinib could offer as a new treatment option for patients with relapsed/refractory PTCL, especially considering the difficulties posed by today's therapies, none of which hold full FDA approval for this indication; on a related note, an abstract will be published in the American Society of Hematology, or ASH, annual meeting abstract supplement covering research by a team from Memorial Sloan Kettering Cancer Center that lends further support to soquelitinib's mechanism of action. The MSK team examined pre- and post-treatment biopsy material from three patients in our Phase 1 trial who had cutaneous T-cell lymphomas, a Th2-derived malignancy involving the skin. With highly sophisticated spatial transcriptomics, they demonstrated that response to soquelitinib was tied to blocking GATA3 signaling, the master regulator of Th2 cells, which led to fewer Th2 cells in the skin. I bring up this work because it matters for treating both PTCL and atopic dermatitis, and it adds to the expanding body of knowledge that supports the remarkable immunologic properties of soquelitinib. Turning now to soquelitinib in atopic dermatitis. The data we have seen so far keep us quite enthusiastic, and we are pushing development and enrollment in the Phase 2 Sierra-1 trial forward as fast as we can. Roughly 200 patients are slated for this trial, among them individuals with prior systemic therapy exposure, spread across three dose levels of soquelitinib plus a placebo arm. Treatment runs for 12 weeks, followed by a 90-day period off drug for follow-up. Enrollment is proceeding in line with our expectations, and we expect topline results in the third quarter of 2027. Should Sierra-1 read out successfully, we intend to move soquelitinib into a Phase 3 program resembling those of other approved systemic atopic dermatitis therapies. That program would include a primary endpoint built on EASI score and IGA score at 12 or 16 weeks of therapy versus placebo. If Sierra-1 stays on its current timelines, we could find ourselves ready to launch a Phase 3 trial in 2028. Our aim is to get soquelitinib to patients as quickly as we can, and then to broaden the clinical evidence and the label through post-marketing studies examining some of its more distinctive features, such as how long responses last after treatment ends; alongside our own work, Angel Pharmaceuticals, our partner in China, is running a Phase 1b/2 clinical trial that could add further evidence supporting soquelitinib's safety and efficacy in atopic dermatitis, while also moving its development ahead in China. The Angel trial's design resembles that of our Phase 2 trial, and it is open at a number of leading dermatology centers in China that have taken part in numerous global registration trials. It is double-blind and placebo-controlled. Angel has finished enrollment in Cohort 1, comprising 24 patients randomized evenly to soquelitinib at 100 milligrams twice per day, 200 milligrams once per day, or placebo. These are the same lower dose levels that were studied in our Phase 1 trial, though the treatment period is longer — 12 weeks rather than 4 weeks. As you'll recall, we saw evidence of efficacy at these lower doses in our Phase 1 trial with 4 weeks of therapy; we have been collaborating closely with the Angel team on the trial, including reviewing photographic images of disease from every single patient. On the current timeline, we expect Angel and Corvus to announce preliminary data in March 2027. That timing allows all patients to complete 12 weeks of therapy plus at least a 30-day post-treatment follow-up period, which lets Angel and us stay blinded until then. Physicians and patients will remain blinded through the full 90 days post-treatment, enabling us to assess durability of response. We are pleased with how the Angel trial is progressing, and we are tracking blinded baseline patient characteristics. I can report that Angel's patients show baseline clinical characteristics similar to those enrolled in our Phase 1 atopic dermatitis trial. One thing that's drawing a lot of our attention — and honestly, we're quite enthusiastic about it — is that the Asian American patients in Corvus's Phase 1 trial look very much like the patients who were enrolled in the Angel trial, which was run in Chinese patients. In our Phase 1 trial, Asian Americans made up 11%, or 8, out of the 72 patients in total. What our testing reveals is that these Asian American patients, at baseline, had markedly higher serum IL-17 levels than the remainder of our non-Asian population and also than a group of healthy volunteers. That matches what the literature reports: Asian patients, along with certain other populations affected by atopic dermatitis, show a larger Th17 disease component, which makes them harder to treat using existing therapies that target only Th2 pathways. According to a recent report, some patients have atopic dermatitis and psoriasis coexisting, whether at the same time or as a consequence of phenotype switching between the two brought on by treatment. We expect Angel to start enrolling patients in Cohort 2 this month, November, and data from Cohort 2 could potentially be available in the second half of 2027. Cohort 2 will involve 24 patients randomized evenly to soquelitinib at doses of 200 milligrams twice per day, 400 milligrams once per day, or placebo.
Richard Miller
executiveFrom the 48 patients we're observing in Cohorts 1 and 2, our expectation is that 60 to 90 more will be enrolled during the Phase 2 portion of the trial. Turning to Corvus, a Phase 1b study of soquelitinib in moderate to severe hidradenitis suppurativa patients began in September. Biologic therapies have been approved for HS, yet many patients remain in need of new choices, since existing treatments either fall short on efficacy or lose their benefit over time. The currently approved drugs primarily target IL-17, a key downstream cytokine produced by Th17 cells, which serve as the principal drivers of this condition. We believe soquelitinib is in a strong position for HS, and there are three reasons why. First, in our atopic dermatitis trial and in other work, we've demonstrated that it brings down both Th17 and Th2. Second, preclinical studies have shown a reduction in fibrosis, which is another hallmark of HS. And third, it is an oral therapy, while most approved products and development candidates in this category are injectable biologics. The Phase 1b HS trial is designed to enroll as many as 25 patients. All patients will receive soquelitinib 200 milligrams twice daily for 12 weeks, followed by a 90-day follow-up period without treatment. The primary endpoint of this trial consists of safety and tolerability. The primary measure of efficacy is how many patients reach Hidradenitis Suppurativa Clinical Response—that is, HiSCR 50 or 75—by week 12. Our plan is to conduct an intensive assessment of biomarkers in skin and blood, examining Th17, Th2, Tregs, and associated effects. Enthusiasm for our HS study has been extremely high. We have been open for roughly 1 month only, yet enrollment is running ahead of schedule, which could put us in position to report data during the first half of 2027. Progress is also occurring on the asthma side, including our intention to enroll patients with both the allergic, or eosinophilic, form of asthma and the non-allergic form, which are also called T2 and non-T2. The majority of asthma medications and the majority of clinical trials focus solely on allergic T2 patients. Our mechanism of action leads us to expect it will work in both T2 and non-T2 disease, so we plan to enroll patients of both types. As many as 40% of asthma patients fall into the non-T2 category, and they need new and improved treatments. An interim analysis is part of the trial design, and it gives us the option to stop a disease type—T2 or non-T2, for instance—should futility emerge. We remain on schedule to launch the asthma trial during the first quarter of 2027. I'd also like to give an update on our work in ALPS—autoimmune lymphoproliferative disease—a study that NIAID is leading. We picked initial data from three patients who were enrolled in the trial and had been treated for a year for a poster at the ASH meeting in December, and the abstract tied to it came out yesterday. What we're observing is consistent with the safety profile we established in our lymphoma and atopic dermatitis studies, and all three patients had a positive response to therapy. Here are the main points — beginning with safety: all three patients completed a full twelve months on the 200 milligram dose administered twice daily. The therapy was well tolerated; treatment was not interrupted, and no Grade 3 or 4 adverse events were reported. Now regarding what we observed clinically, here's how it played out across the three ALPS patients: all three managed to discontinue their prior therapies, which included corticosteroids as well as immunosuppressive agents; a reduction in circulating proliferating double-negative T cells — the disease-driving cells in ALPS — was documented in two of the three, whereas the third entered with such minimal circulating numbers that measurement proved difficult; spleen enlargement shrank in two of the three; and additional disease-associated markers showed improvement as well. With these findings in hand, we plan to hand the soquelitinib IND for ALPS over to Corvus. We intend to sit down with the FDA in order to expand how many treatment centers there are, and to bring down the age cutoff so that pediatric patients can be enrolled. Broadly speaking, we feel we are carrying out a plan designed to verify the wide-ranging promise of soquelitinib as well as ITK inhibition in a variety of Th2- and Th17-driven diseases. Come 2027, we have important milestones throughout our pipeline, with clinical trials spanning four sizable market opportunities: PTCL, atopic dermatitis, hidradenitis suppurativa, and asthma. Adding to that is Angel, which is anticipated to conduct trials in atopic dermatitis and asthma, together with the NIAID study in ALPS that is moving over to Corvus. Here's a quick look at the milestones we expect in 2027: first ALPS data will be presented at ASH in December; a Phase 3 PTCL interim futility analysis is expected during the first quarter; Angel Pharmaceuticals will report atopic dermatitis Cohort 1 data in March; hidradenitis suppurativa Phase 1b results should arrive in the first half of 2027; Corvus Sierra-1 Phase 2 data is slated for the third quarter; Angel Pharma Cohort 2 data will come in the second half of the year; and Phase 3 PTCL topline results are expected before 2027 ends. In addition, Corvus and Angel both plan to start asthma trials in 2027. When we look across what we're developing, the central idea is how uniquely ITK inhibition works — it rebalances the immune system through influencing multiple important cell activities using a pill taken by mouth that has shown a quite encouraging safety picture to date. We're eager to share news about how things are advancing on upcoming calls. At this point I'll turn things over to the operator so we can begin Q&A. Operator?
Li Watsek
analystHey, thanks, guys, for taking my questions. Just regarding the Angel data, it looks like it's been pushed out by a quarter. Maybe help us understand why the timeline shifted. You noted that the baseline characteristics in the trial are very similar to the U.S. trial. Just wondering which cohort are you referring to, given there's some variabilities between cohorts?
Richard Miller
executiveLi, thanks for the question. I assume you're referring to the atopic dermatitis trial by Angel. In the Angel patients enrolled so far, that's their first cohort, their baseline characteristics, blinded baseline characteristics we can look at, things like age, gender, etc., other, mean EASI scores, etc. Comparing that with the 72 patients in our whole Phase 1 trial, the characteristics line up very closely on age, EASI scores, IGA scores, and so on. That prompted us — we are, of course, following Angel with great care — to revisit cytokine data from Asian participants in the Corvus Phase 1 study. Naturally, some Asians do enroll in American trials, and among those individuals the baseline features closely mirror those of the Chinese patients. What interests us most is that numerous papers report a pronounced IL-17, Th17 component in Asian atopic dermatitis patients. We verified that among our Asian patients in the U.S. The Angel trial is proceeding as expected. We have taken great care regarding which patients are chosen, documenting disease through photographic images, and operating at the finest centers in China, so enrollment is proceeding per the plan. Also, prior to revealing any data, we wanted the complete 12 weeks of therapy along with 30 days of follow-up, and throughout that time we stay blinded — the company, the patients, the doctor, everyone; that is why we have stretched that out somewhat. Is that responsive to your question?
Li Watsek
analystYes, thank you very much.
Graig Suvannavejh
analystGood afternoon. Richard, thanks for fielding my question. Congrats on the progress and all the updates. I've got a question — actually two, if you don't mind. First, about the futility analysis that you'll be announcing in Q1 of next year, I think you mentioned in your prepared remarks that essentially you'll just be putting out something along the lines of a yes-or-no answer and won't be disclosing any safety or efficacy. Does that hold either way? To put it differently, if a futility analysis came back negative, would you still prefer not to share the safety/tolerability data? I just wanted clarification on that and maybe the reasoning. Second, regarding your hidradenitis suppurativa readout, my understanding is that the primary efficacy endpoints are HiSCR 50 or 75. I was just wondering if you will also share — or have you built any lesion-based clinical endpoints into the study, and will any of those be shared? Thanks.
Richard Miller
executiveThanks, Graig. On the futility analysis, if the study goes forward, we would just inform people of that; making data public at that stage would not be appropriate, since one could argue it might bias the rest of the study; that is fairly typical. So, if the trial comes back negative and you halt it, then sure, at some point you'd be able to release the data. On your second question regarding HS, we're tracking additional measures in that condition. Our interest extends beyond just nodules—we're also evaluating abscesses, tunnels, draining tunnels, and similar features. HS has us enthusiastic because we now feel quite confident that we're impacting Th17. Th17 plays a key role in asthma as well as HS. These lesions contain many neutrophils, which arise through Th17-driven effects. It all ties together. The diseases we picked were chosen for a specific reason, grounded in how soquelitinib works. On the HS endpoints, all the measures you listed will be examined — nodule count, which is essentially HiSCR — but we're quite focused on the other components, abscesses and tunnels, since we've already reported that soquelitinib affects fibrosis through what is a Th2-mediated mechanism; that work was published last year and presented at the ACR meeting, in a mouse model of systemic sclerosis. I hope that addresses your question, Greg.
Graig Suvannavejh
analystYes, that answers it, thanks. I’ve got one brief follow-up regarding your ALPS program. It’s notable that the IND will be handed over to Corvus, and can you verify those are the identical doses tested previously? Also, since this patient population is, I think, more of a rare orphan-type situation instead of a broader one such as asthma or atopic dermatitis, how are you approaching dosing or pricing—ultimately, I suppose, if you were to achieve success across all those indications?
Richard Miller
executiveTo date, the ALPS patients have been adults. The patients have ranged in age from 30 to 40 years, and the dosing has been 200 milligrams BID — identical to what we're using in lymphoma and in AD. Now, ALPS is primarily a pediatric disease, so we plan to meet with FDA and expand into a pediatric population, adding more sites. We're taking over the IND because we want greater control over this study. Obviously, once we move into a pediatric population, doses may change simply based on the size of the individuals involved. I think the value of ALPS lies in what it teaches us about our drug, about ITK, and about the immune system. At present, we work in T-cell lymphoma and autoimmune diseases. ALPS falls right at the boundary where those two fields meet, and the ALPS patients have taught us an enormous amount. Beyond verifying the safety profile we had already observed in a notably ill group, it has supplied substantial insight into additional conditions we might pursue down the road. As for pricing and commercialization, I'd say it's somewhat premature to discuss those.
Graig Suvannavejh
analystOkay, thank you very much.
Cha Cha Yang
analystHello everybody, this is Jacha speaking on Roger's behalf. I've only got two questions. To start, I'd like a confirmation regarding your Phase 2 AD patients — you said they had failed at minimum one systemic or topical therapy, but is it correct that they may not have failed dupi or a JAK necessarily? The second is about your HS study. Could you give us some sense of the data benchmarks soquelitinib would have to achieve to be competitive in that area?
Richard Miller
executiveThanks for asking. I want to clarify the details of our Phase 2 study. To qualify, a patient needs to have tried and not succeeded on either a topical corticosteroid or a systemic therapy — and some have failed additional treatments beyond that. Patients who didn't respond to dupi, to a JAK inhibitor, to other therapies, or to our systemic corticosteroids are welcome in our studies. That, I think, is what distinguishes us from most other trials. Someone can come in having failed dupi — in fact, if you go back to the Phase 1 data we showed at SID, a number of patients had previously failed JAK inhibitors or Dupixent. So why does that get us excited? Our mechanism of action has no overlap with those mechanisms, so cross-resistance wouldn't be expected — and we never observed any. Turning to the second question about HS: what do we anticipate seeing? Regarding your question about what we anticipate: it's a trial in which we now have strong biomarkers available for investigation. We understand which markers to focus on — IL-17, Th17s, and the related transcription factors. Myeloid cells are also going to be quite compelling in that context, and here's something unexpected — B cells are present in large numbers within HS lesions. I'd also note that ALPS patients show abundant B cells; although this is a T-cell disease, their lesions contain many B cells. Our ASH poster includes some of that work in this area. B cells are driven by T cells. In any case, we're going to review everything there, and I believe we'll develop a solid sense of whether efficacy is showing up. The moment we observe that, there's no need to hold off until every one of the 25 patients has been treated. Planning can begin on a more definitive Phase 2 that is randomized and placebo-controlled. Waiting until the end isn't necessary. Does that address your question?
Cha Cha Yang
analystThat's quite useful. Thank you.
Jeff Jones
analystGood afternoon, everyone, and I appreciate you taking my question. Perhaps, just following up on the HS question, when you consider the other studies out there in this field, do you have any sense of the benchmarks or hurdles you'd want to observe — what level of efficacy or signal would you need to see in order to support moving forward? And then I have one follow-up.
Richard Miller
executiveYes. I believe the benchmarks for HiSCR 70 are 70 and 50. For HiSCR 50, you'd want to see 50%, 60% of patients achieving that. For HiSCR 75, perhaps around 30%. I think if we reach that or better, we'd be pleased with such a result for an oral agent that has a good safety profile. Naturally, I didn't discuss it much during this call, but we're very interested in durability of response.
Jeff Jones
analystYep. Great. Appreciate that.
Richard Miller
executiveThen
Jeff Jones
analystMoving to a follow-up, I suppose. On the AD side, it's clearly quite compelling, as you were just mentioning, around certain patient recruitment efforts and enabling some of these individuals who've already not responded to more advanced therapy. With the data you've gathered so far, how do you view soquelitinib's potential place within the treatment landscape, considering the different biologics and approved agents available and some of the bispecifics that are moving forward? Are there specific patient subsets where you believe soquelitinib would be especially well suited?
Richard Miller
executiveFrom what we've observed to date in our Phase 1 study, from our safety profile, and from our mechanism, our view is that soquelitinib can serve as an upfront treatment for patients with moderate to severe AD, or it can be given in the relapse setting for patients who've already received other therapies. Now bear in mind, plenty of other therapies exist out there at present, and the pool of patients who are prior systemic therapy-experienced keeps growing, which we in fact anticipated a couple years ago when we began working in this area. Jeff, I think the answer is we have every reason to believe that you could use this as a first-line systemic therapy or later line.
Jeff Jones
analystGreatly appreciate it. Thanks, guys.
Richard Miller
executiveThank you, Jeff.
Sean Lee
analystHi there, good afternoon, and thank you for taking my question. I had one regarding the asthma study. We saw that the beginning has been pushed back a bit, to early next year. What was the reason behind that delay? And have you settled on which kinds of patients will be recruited for this study, in terms of the thresholds for the T2 and non-T2 groups?
Richard Miller
executiveWe had spoken about starting asthma in late December. Since it's Christmas and New Year's, we decided it would be safer to say January. That timeline hasn't materially changed. In fact, our IND has already gone through FDA and everything is fine. What was the second part of your question again?
Sean Lee
analystFor T2 and non-T2 patients, there are the patient types and the predefined groups.
Richard Miller
executiveThe what are they? Sorry, I didn't catch that.
Sean Lee
analystNo—do you folks have any thresholds that are predefined for
Richard Miller
executiveOh, yeah! Got it, I see what you're asking. My apologies, I misunderstood. Eosinophils sit at 150. Above 150 means you're a T2, and under 150 means you're not T2. Beyond that, we also check the forced expiratory NO—nitric oxide—which comes in above 25 for the T2; that's very typical. So our cutoff is 150.
Sean Lee
analystAll right, understood. Thanks for that.
Richard Miller
executiveAre there any other quest — Zack?
Sean Lee
analystNo.
Richard Miller
executiveAll right. Operator, I believe there are no further questions. I'd like to thank all of you for joining our conference call. We look forward to bringing you updates down the road. Thanks to each of you.
Operator
operatorLadies and gentlemen, this concludes today's conference call. You may now disconnect. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.